Fig. 4From: A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccineIn vivo study showing tumor specific CD8+IFN-γ+ T cell induction and tumor prevention effects with a DC-based cancer vaccine using the RPS3 protein as adjuvantBack to article page